top of page

By directly accessing biomarkers in the skin, Microwearable™ devices enable instant diagnosis and monitoring of a range of disorders in a simple, painless wearable format whilst continuously sharing the results to the user, health professionals and others

​

Blood-Derived Data

Immediate

image of body and WO.png

continuous

Anywhere

Painless

​

Simple

Anytime

Low Cost
WO ADVANTAGE
Asset 2@4x.png

                 DATA

​

Quality and quantity

​

Real-life, real-time data

​

Continuous

Asset 10@3x.png

             COSTS

​

Costs approx. 1/10th of blood-based assay

​

Greater productivity - better utilisation of staff and resources

​

Reduced burden on healthcare systems 

Asset 8@3x.png

                   TIME​

 

Applied rapidly

​

Minimal waiting time -results within minutes (locally and remotely)

Radically changing healthcare management

We are prioritising these healthcare challenges

Asset 7@3x.png

Cardiovascular Disease

 Cardiovascular disease is the biggest cause of death in the world. Elevated troponin levels are key to the diagnosis of myocardial infarction. Continued monitoring of relevant biomarkers of heart failure by wearable devices can permit appropriate early medical intervention and ongoing management saving lives and money

Asset 4 (2)@3x.png

Clinical Trials

Cardiotoxicity may be a major side effect in patients receiving chemotherapies and immunotherapies. Delays in clinical trials can cost millions of dollar per day. Non invasive wearable devices can increase clinical trial effectiveness

Worker Health &

Safety

Asset 3.png

Dehydration affects physical and cognitive capability leading to risk of injury, death, lost productivity, higher business costs and risk of legislative non compliance. 

 

​

​

​

​

Asset 10@3x.png

Aged Care

20-50% of long-term care residents are chronically dehydrated which significantly increases the likelihood of falls, injuries, delirium, cardiac events and renal failure.  Simple, non invasive hydration monitoring enables preventative treatment resulting in improved care, higher staffing productivity, better risk management and reassurance of carers and comforters

Analytics

Asset 13@3x.png

Aggregation of anonymised health data linking disease patterns with real time biomarker evidence enables population health policy design and insights into new interventions.  

Asset 1@4x.png

Remote Healthcare

The medical community is well aware of the inability of our current models of care based on bedside interactions and in-hospital interventions to scale with increasing populations and the need to deliver healthcare to remote and rural locations. Healthcare-in-the-home and telemedicine are welcome technological answers to this problem. MicrowearableTM devices are, at their core, Internet-of-Things (IoT) medical devices and can seamlessly integrate into these evolving models of care.

contact us

Collaborate with us

​

WearOptimo is building a portfolio of strategic  partnerships to radically improve the health of the global community.

We welcome conversations  with organisations who can help us take the Microwearable  device to those who can benefit  from it the most.

Enable us

WearOptimo is interested in conversations with potential investors who are passionate about making a difference.

Early investors have the opportunity to maximise their impact through partnering with WearOptimo's cornerstone investor, the Australian National University.

Work with us

WearOptimo is building a world leading team who are passionate about making a difference.

Visit our About Us page to learn about specific opportunities or send us an email to let us know of your interest and capabilities.

 

​

Our Partners

Australian National University Logo.jpg
australian-government-stacked-black copy
MTP Connect Logo.jpg
Queensland-Government-Health.png
AM_Logo_RGB_HR_0_162_221.jpg
bottom of page